



Liver Cancer

Quick Reference Guide

2026

Table of Contents

1. CLINICAL SNAPSHOT	3
HCC/RAF V28 Mapping	3
2. RECOGNITION AND DIAGNOSIS	5
Clinical Diagnostic Workups Covered Under Medicare Part B (high-risk populations)	5
Subtle Early Signs in Older Adults	7
Geriatric Risk Factors	8
Diagnostic Thresholds — LI-RADS and Surveillance	9
Cardinal Symptoms	10
Common Oversights	11
Key Differentials in Elderly	11
Comorbidity Screening	12
BCLC Staging — Treatment Options	13
Populations At Risk	14
3. MEAT DOCUMENTATION ESSENTIALS	14
Clinical Documentation Elements	15
Reframing Common Documentation Shortcuts	15
4. TREATMENT AND REFERRAL QUICK GUIDE	17
Therapy Escalation Criteria	17
NCCN-Aligned First-Line Systemic Therapy (BCLC C)	18
Non-Pharmacologic Care and Supportive Interventions	19
Medication Safety and Key Interactions	20
When to Refer	21
Follow-Up Timing	22
Comorbidity Management — Primary Care Role	22
Cost-Smart Options	23
Patient Education and Adherence	24
Quality Metrics Tie-In	25
5. CODING REMINDERS AND CASE EXAMPLES	26
Coding Specificity	27
Annual Clinical Review and Confirmation	28
Good Documentation is Comprehensive Coding	28
EHR Workflow Tips	29
Brief Case Examples	30
REFERENCES	31

1 CLINICAL SNAPSHOT

Definition: Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver (~75–85% of primary liver cancers) and arises predominantly from hepatocytes in the setting of chronic liver disease.¹ Cirrhosis is present in >80% of cases;¹ the dual diagnostic challenge of HCC and the failing liver must both be managed simultaneously. Liver cancer incidence in the US has tripled over the past four decades,² driven by the convergence of three epidemics: HCV (birth cohort 1945–1965, now Medicare-aged), MASLD/NASH fueled by obesity and type 2 diabetes, and historically undertreated HBV.³

ICD-10 Codes:

Primary tumor: **C22.0** (liver cell carcinoma — most common; preferred over C22.8/C22.9), **C22.1** (intrahepatic cholangiocarcinoma), **C22.2–C22.4** (rare histologies), **C22.7** (other specified), **C22.8** (unspecified type — **AVOID**), **C22.9** (not specified as primary or secondary — **AVOID**, commonly overused). Secondary/metastatic liver involvement: **C78.7** (secondary malignant neoplasm of liver and intrahepatic bile duct). **Status code:** **Z85.05** (personal history — only after complete eradication and end of active surveillance). Concurrent **comorbidities to code:** **K74.60** (cirrhosis), **B18.2** (HCV), **B18.0/B18.1** (HBV), **K75.81/K76.0** (NASH/MASLD), **E11.x** (T2DM), **K76.6** (portal hypertension), **Z94.4** (liver transplant status), **K76.82** (hepatic encephalopathy).^{4,5,6}

Prevalence and Burden: Approximately **42,340 new cases** of primary liver and intrahepatic bile duct cancer projected in the US in 2026 (27,790 men; 14,550 women), with **30,980 deaths**.² **5-year survival across all stages remains below 20%**; most patients are diagnosed at intermediate or advanced BCLC stages when curative options are foreclosed.⁷ **Incidence is rising most rapidly in adults ≥60 years** and in rural areas (5.7% annual increase).⁸ Black patients have 50% higher incidence and are diagnosed at more advanced BCLC stages (74% at stage C/D vs 57% in White patients).⁸ **HCV effect on HCC risk strengthens with age:** HR 22.51 at age ≥70 vs HR 5.72 at age 50.³ Surveillance utilization remains ~24% across all settings; only ~16% achieve guideline-concordant semiannual surveillance.^{9,25}

HCC/RAF V28 Mapping

ICD-10 CODE(S)	HCC CATEGORY (V28)	RAF (CNA)	DOCUMENTATION REQUIREMENT
C22.0 Hepatocellular carcinoma (primary)	HCC 22 — Bladder, Colorectal and other Cancers (incl. hepatocellular carcinoma) ¹⁰	0.363	Active primary liver malignancy confirmed by imaging (LI-RADS LR-5) or biopsy; ¹¹ document 'hepatocellular carcinoma' explicitly to support C22.0 — preferred over C22.8/C22.9

AAVBC Knowledge Hub Premium Content Access

Continue reading your guide
with an AAVBC subscription

[Subscribe Now](#)

Already a subscriber? [Sign in](#)

Limited offer

Basic Membership Free

Includes access to downloadable Quick Reference Guides, mailing list for industry updates/medical information, research toolkits, AAVBC events and so much more!

Cancel at any time